Lilly Drug Combo Fights Arthritis & Obesity

A recent late-stage clinical trial conducted by Eli Lilly has showcased the efficacy of its drug Zepbound when used in conjunction with Taltz for treating psoriatic arthritis and obesity. The study demonstrated that this combination therapy not only improved the symptoms of psoriatic arthritis but also led to significant weight loss.

Results indicated that a substantial portion of patients on the Zepbound and Taltz combination met primary study goals, which included a significant reduction in disease activity and considerable weight loss after 36 weeks. This outcome was markedly better than that observed in patients receiving Taltz alone.

The trial involved overweight or obese adults diagnosed with active psoriatic arthritis, many of whom also had additional weight-related health conditions. The findings suggest a potential new standard of care for such patients, offering a comprehensive approach to managing their complex health needs.